• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

One Drop touts effects of diabetes management mobile app

August 25, 2017 By Sarah Faulkner

One Drop mobile appOne Drop touted data today from a retrospective study of people with Type I and Type II diabetes using its mobile diabetes management app.

The data, which were published yesterday in JMIR Diabetes, showed that people using the One Drop mobile app had a 1.1% to 1.3% absolute reduction in A1C in 4 months.

The app is available for iOS and Android systems and allows users to manually and passively store, share and track their data using Apple HealthKit, Google Fit or One Drop’s Chrome blood glucose meter. Users can also schedule insulin reminders, view their stats, set goals and talk with other users.

“We used real-world data to produce timely and relevant results,” Dr. Chandra Osborn, One Drop’s VP of health & behavioral informatics, said in prepared remarks. “More often than not, relevance and the gold standard randomized controlled trial are at odds. We didn’t perform a RCT on outdated technology. We studied current technology and recent data, and found A1c improved among people using the One Drop app. We also linked that improvement to tracking self-care with the app.”

“From study to publication in less than 3 months is unheard of. That’s impossible to do with a RCT. When it comes to technology, relevance and speed are everything.”

“Prior to this study, the scientific literature told us that diabetes mobile apps could potentially improve A1c by -0.45%,” founder & CEO Jeff Dachis added. “I’m thrilled to present evidence that says otherwise. We are seeing dramatic improvements in A1c — often achieved with drugs, but rarely, if ever, seen with digital therapeutics and self-care interventions. And, in this case, we’re doing it all at scale for less than a fraction of the cost of current standards of care: free.”

See the best minds in medtech live at DeviceTalks Boston on Oct. 2. 

Filed Under: Big Data, Clinical Trials, Diabetes, Featured, Pharmaceuticals, Technology Tagged With: onedrop

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Reader Interactions

Comments

  1. David Kliff says

    August 26, 2017 at 3:05 pm

    You should really know better than to report this – did you read the study closely the A1c data is SELF REPORTED This is typical of One Drop and should not be dignified with publication by your fine site

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS